{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-268840","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.290065+00:00","generated_at":"2026-06-09T00:02:20.033455+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Karyopharm Q3 revenue $36.0M, net loss $0.30/sh; FY guidance reaffirmed","bullets":["U.S. XPOVIO net product revenue $30.2M, down from $32.0M year-over-year due to PAP use and 340B discounts.","Net loss of $34.5M ($0.30/sh) improved from $36.3M ($0.45/sh) in Q3 2022; cash $209.2M as of Sept 30, 2023.","Full-year 2023 guidance held: total revenue $145-160M, XPOVIO net revenue $110-125M, non-GAAP opex $240-255M.","NCCN elevated XVd to preferred category 1 for lenalidomide-refractory multiple myeloma after 1-3 prior lines.","Entered clinical collaboration with BMS to evaluate mezigdomide + selinexor in R/R myeloma post T-cell therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-268840","json":"https://secwatch.observer/filing/0001193125-23-268840.json","markdown":"https://secwatch.observer/filing/0001193125-23-268840.md","text":"https://secwatch.observer/filing/0001193125-23-268840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523268840/0001193125-23-268840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523268840/d578470d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:02:20.033455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d2a2de9247d3e0add758bfd252b8617035a87d9c","claim":"Karyopharm Therapeutics Inc. reported the quarter ended September 30, 2023 results: revenue $36.0 million. Guidance reaffirmed.","evidence_excerpt":"Total revenue for the third quarter of 2023 was $36.0 million, compared to $36.1 million for the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523268840/0001193125-23-268840-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$36.0 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}